Practical Considerations for Selecting and Administering Treatment in mHSPC
May 19th 2023Expert panelists consider the possibility of taking a break from treatment given a patient’s response to therapy along with other unique management strategies in the setting of metastatic hormone-sensitive prostate cancer.
Daniel P. Petrylak, MD, Reviews Ongoing Clinical Trials in Bladder Cancer
April 22nd 2022At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.
Avelumab Maintenance for Urothelial Carcinoma: Real-World Evidence
December 22nd 2021Daniel Petrylak, MD and Donald Barry Boyd, MD, MS, examine real-world data presented in the recent publication, “Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.”
Focus on Transitional Disease: A Critical Interval to Delay Progression of Prostate Cancer
April 19th 2021ONCOLOGY® editorial board member E. David Crawford, MD, and colleagues, propose a new model for guiding the treatment of prostate cancer that focuses on a “transitional state,” which occurs during the interval of progression to metastatic castration-resistant prostate cancer.
ASCO: Role of Chemotherapy and Novel Targeted Agents in Prostate Cancer
May 30th 2014As part of our coverage of ASCO's Annual Meeting, we discuss the role of chemotherapy in prostate cancer, as well as study results on novel targeted approaches and agents in development for prostate cancer that will be presented at the meeting.